Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Becotatug Vedotin (MRG003) Combined With Anti-PD1 as Maintenance Therapy for Recurrent and Metastatic Nasopharyngeal Carcinoma
NCT07705243Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jul 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
A Phase 3 trial of becotatug vedotin in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Started Jul 2026; status: recruiting.
02
Drugs
becotatug vedotin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07705243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07705243.